{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(6)"],"submitter":["Jalbert JJ"],"funding":["Regeneron Pharmaceuticals"],"pubmed_abstract":["<h4>Introduction</h4>Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibody treatment among patients with COVID-19.<h4>Methods</h4>This retrospective cohort study linked Komodo Health and CDR Maguire Health and Medical data. Patients diagnosed with COVID-19 in ambulatory settings (August 1-October 30, 2021) treated with SC CAS+IMD were exact- and propensity score-matched to fewer than five untreated treatment-eligible patients and followed for the composite endpoint of 30-day all-cause mortality or COVID-19-related hospitalization. Kaplan-Meier estimators were used to calculate outcome risk over"],"journal":["Infectious diseases and therapy"],"pagination":["2125-2139"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526200"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19."],"pmcid":["PMC9526200"],"pubmed_authors":["Murdock D","Wang D","Jalbert JJ","Hussein M","Mastey V","Sanchez RJ","Bussey J","Hirshberg B","Weinreich DM","Wei W","Farinas L","Duart C"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19.","description":"<h4>Introduction</h4>Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibody treatment among patients with COVID-19.<h4>Methods</h4>This retrospective cohort study linked Komodo Health and CDR Maguire Health and Medical data. Patients diagnosed with COVID-19 in ambulatory settings (August 1-October 30, 2021) treated with SC CAS+IMD were exact- and propensity score-matched to fewer than five untreated treatment-eligible patients and followed for the composite endpoint of 30-day all-cause mortality or COVID-19-related hospitalization. Kaplan-Meier estimators were used to calculate outcome risk over","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-05T11:40:11.384Z","creation":"2025-04-05T11:40:11.384Z"},"accession":"S-EPMC9526200","cross_references":{"pubmed":["36181639"],"doi":["10.1007/s40121-022-00691-z"]}}